517 related articles for article (PubMed ID: 16885403)
1. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
Marckmann P; Skov L; Rossen K; Dupont A; Damholt MB; Heaf JG; Thomsen HS
J Am Soc Nephrol; 2006 Sep; 17(9):2359-62. PubMed ID: 16885403
[TBL] [Abstract][Full Text] [Related]
2. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
Marckmann P
Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
[TBL] [Abstract][Full Text] [Related]
3. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
4. Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
Marckmann P; Skov L; Rossen K; Heaf JG; Thomsen HS
Nephrol Dial Transplant; 2007 Nov; 22(11):3174-8. PubMed ID: 17483196
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
Khurana A; Runge VM; Narayanan M; Greene JF; Nickel AE
Invest Radiol; 2007 Feb; 42(2):139-45. PubMed ID: 17220732
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
10. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
[TBL] [Abstract][Full Text] [Related]
12. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
[TBL] [Abstract][Full Text] [Related]
13. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
Michelet PR; Chopard CS; Martin PY; Vallée JP
Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: epidemiology update.
Marckmann P
Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
Jakobsen J
Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
[No Abstract] [Full Text] [Related]
16. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide.
Leiner T; Herborn CU; Goyen M
Eur Radiol; 2007 Aug; 17(8):1921-3. PubMed ID: 17458550
[No Abstract] [Full Text] [Related]
17. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
18. Gadodiamide-associated nephrogenic systemic fibrosis.
Karlik SJ
AJR Am J Roentgenol; 2007 Jun; 188(6):W584; author reply W585. PubMed ID: 17515359
[No Abstract] [Full Text] [Related]
19. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
20. Extracellular Gd-CA: differences in prevalence of NSF.
Thomsen HS; Marckmann P
Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
